http://blog.pharmtech.com/2012/02/06/is-the-us-facing-a-pharmaceutical-manufacturing-gap/ The blog of Pharmaceutical Technology magazine Thu, 09 May 2013 23:30:55 -0400 http://wordpress.org/?v=2.8.4 hourly 1 http://blog.pharmtech.com/2012/02/06/is-the-us-facing-a-pharmaceutical-manufacturing-gap/comment-page-1/#comment-58433 Life Science Manufacturing: An Overlooked Strategic Differentiator | UL Eduneering Wed, 06 Feb 2013 19:18:26 +0000 http://blog.pharmtech.com/?p=5179#comment-58433 [...] second article was called, “Is the US Facing a Manufacturing Gap,” published in Pharmaceutical Technology.  The article poses the question, “in a [...] [...] second article was called, “Is the US Facing a Manufacturing Gap,” published in Pharmaceutical Technology.  The article poses the question, “in a [...]

]]> http://blog.pharmtech.com/2012/02/06/is-the-us-facing-a-pharmaceutical-manufacturing-gap/comment-page-1/#comment-43662 Mike Wokasch Tue, 07 Feb 2012 17:25:13 +0000 http://blog.pharmtech.com/?p=5179#comment-43662 Pharmaceutical manufacturing has been considered a cost center and easy place to cut costs to improve the bottom line. On the other hand, because of the sizable investments needed for maintaining facilities and processes, the multidisciplinary expertise required to do it right, and the challenges and complexities of consistently manufacturing cGMP - compliant prescription drugs, the book Pharmaplasia proposed that contract manufacturing could represent a yet to be recognized major profit center for Big Pharma. Unfortunately, few Big Pharma executives have any appreciation for pharmaceutical manufacturing complexities, the expertise required has retired or been laid-off, and companies are finding it increasingly difficult to meet even minimum cGMP quality and regulatory requirements. Pharmaceutical manufacturing has been considered a cost center and easy place to cut costs to improve the bottom line. On the other hand, because of the sizable investments needed for maintaining facilities and processes, the multidisciplinary expertise required to do it right, and the challenges and complexities of consistently manufacturing cGMP – compliant prescription drugs, the book Pharmaplasia proposed that contract manufacturing could represent a yet to be recognized major profit center for Big Pharma. Unfortunately, few Big Pharma executives have any appreciation for pharmaceutical manufacturing complexities, the expertise required has retired or been laid-off, and companies are finding it increasingly difficult to meet even minimum cGMP quality and regulatory requirements.

]]>